Copyright
©The Author(s) 2019.
World J Cardiol. Jan 26, 2019; 11(1): 24-37
Published online Jan 26, 2019. doi: 10.4330/wjc.v11.i1.24
Published online Jan 26, 2019. doi: 10.4330/wjc.v11.i1.24
n = 226 | No plaque, n = 150 | Plaque, n = 76 | P value | |
Age | 63.2 (11.4) | 60.6 (12.1) | 68.2 (7.3) | < 0.001a |
Male sex | 106 (46.9%) | 64 (42.7%) | 42 (55.3%) | 0.099 |
Hypertension | 166 (73.5%) | 100 (66.7%) | 66 (86.8%) | 0.002a |
Diabetes mellitus | 45 (19.9%) | 24 (16.0%) | 21 (27.6%) | 0.058 |
Dyslipidaemia | 124 (54.9%) | 74 (49.3%) | 50 (65.8%) | 0.027a |
Current smoker | 55 (24.3%) | 36 (24.0%) | 19 (25.0%) | 0.999 |
Family history of premature CAD | 17 (7.5%) | 13 (8.7%) | 4 (5.3%) | 0.516 |
BMI, kg/m2 | 33.3 (4.1) | 33.2 (4.5) | 33.4 (3.0) | 0.694 |
Obesity | 0.033a | |||
Grade 1 | 179 (79.2%) | 126 (84.0%) | 53 (69.7%) | |
Grade 2 | 39 (17.3%) | 19 (12.7%) | 20 (26.3%) | |
Grade 3 | 8 (3.5%) | 5 (3.3%) | 3 (3.9%) | |
No cardiovascular risk factors | 29 (12.8%) | 28 (18.7%) | 1 (1.3%) | < 0.001a |
SCORE | < 0.001a | |||
Low-risk, < 1% | 29 (12.8%) | 28 (18.7%) | 1 (1.3%) | |
Moderate-risk, 1%-5% | 113 (50.0%) | 78 (52.0%) | 35 (46.1%) | |
High risk, 5%-10% | 33 (14.6%) | 20 (13.3%) | 13 (17.1%) | |
Very high-risk, ≥ 10% | 49 (21.7%) | 24 (16.0%) | 25 (32.9%) | |
Not classifiable | 2 (0.9%) | 0 | 2 (2.6%) | |
CAD PTP | 0.017a | |||
< 15% | 10 (4.4%) | 10 (6.7%) | 0 | |
15-65% | 180 (79.6%) | 121 (80.7%) | 59 (77.6%) | |
65-85% | 36 (15.9%) | 19 (12.7%) | 17 (22.4%) | |
> 85% | 0 (0%) | 0 (0%) | 0 (0%) | |
Fasting plasma glucose, mg/dL | 113.8 (32.2) | 112.5 (33.4) | 116.6 (29.5) | 0.369 |
Glomerular filtration rate, mL/min/1.73 m2 | 87.6 (25.4) | 91.4 (27.1) | 79.7 (20.3) | < 0.001a |
Total cholesterol, mg/dL | 199.6 (40.5) | 196.9 (38.5) | 205.0 (43.9) | 0.159 |
HDL cholesterol, mg/dL | 48.6 (12.3) | 49.6 (13.4) | 46.5 (9.1) | 0.043a |
Triglycerides, mg/dL | 143.6 (75.9) | 133.0 (60.0) | 164.8 (97.6) | 0.011a |
LDL cholesterol, mg/dL | 122.1 (34.6) | 120.2 (34.1) | 125.9 (35.8) | 0.257 |
Atrial fibrillation | 26 (11.5%) | 14 (9.3%) | 12 (15.8%) | 0.224 |
Treatment after EE | ||||
Angiotensin-converting enzyme inhibitor | 29 (12.8%) | 16 (10.7%) | 13 (17.1%) | 0.247 |
Angiotensin II receptor blockers | 99 (43.8%) | 54 (36.0%) | 45 (59.2%) | 0.001a |
Beta-blockers | 72 (31.9%) | 44 (29.3%) | 28 (36.8%) | 0.32 |
Calcium channel blockers | 53 (23.5%) | 27 (18.0%) | 26 (34.2%) | 0.011a |
Nitrates | 21 (9.3%) | 13 (8.7%) | 8 (10.5%) | 0.832 |
Statins | 111 (49.1%) | 66 (44.0%) | 45 (59.2%) | 0.043a |
Ezetimibe | 6 (2.7%) | 3 (2.0%) | 3 (3.9%) | 0.673 |
Fibrates | 10 (4.4%) | 5 (3.3%) | 5 (6.6%) | 0.476 |
Omega−3 fatty acids | 4 (1.8%) | 3 (2.0%) | 1 (1.3%) | 1 |
Antiplatelet drugs | 109 (48.2%) | 67 (44.7%) | 42 (55.3%) | 0.172 |
Anticoagulants drugs | 17 (7.5%) | 8 (5.3%) | 9 (11.8%) | 0.137 |
Oral antidiabetic drugs | 28 (12.4%) | 13 (8.7%) | 15 (19.7%) | 0.030a |
Insulin treatment | 5 (2.2%) | 2 (1.3%) | 3 (3.9%) | 0.338 |
- Citation: Vidal-Perez R, Franco-Gutiérrez R, Pérez-Pérez AJ, Franco-Gutiérrez V, Gascón-Vázquez A, López-López A, Testa-Fernández AM, González-Juanatey C. Subclinical carotid atherosclerosis predicts all-cause mortality and cardiovascular events in obese patients with negative exercise echocardiography. World J Cardiol 2019; 11(1): 24-37
- URL: https://www.wjgnet.com/1949-8462/full/v11/i1/24.htm
- DOI: https://dx.doi.org/10.4330/wjc.v11.i1.24